Drug Profile
Research programme: small molecule antibacterial therapeutics - Ricerca Biosciences
Latest Information Update: 27 Mar 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Ricerca Biosciences
- Class Small molecules
- Mechanism of Action FabH inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 20 Jan 2003 Preclinical trials in Bacterial infections in USA (unspecified route)